2022 02 21 diaz capital

Direct issue with Diaz Capital Invest AB finalized at 8.50 DKK

The Extra General Meeting in CS MEDICA A/S (”CS MEDICA” or the ”Company”) decided, on the 3rd of February 2022, to approve the Board of Directions proposal to make a cash capital increase (direct issue) of 100,000 shares to Diaz Capital Invest AB.  Registration of the directed share issue at the Danish Companies Registration Office has now taken place and the total number of shares amounts to 11.002.000 and the share capital to DKK 715.130.      

The Direct Issue between CS Medica and Diaz Capital Invest AB(DIAZ) is now completed.  Diaz Capital comments on their investment;

“We are amazed by CS MEDICA as a company, and we see great potential in the future CBD industry. We believe that CS MEDICA will become a major player in the market and are confident about our investment in the company. The Pfizer deal with Arena Pharmaceutical was an eye opener and cemented our belief that this is a smart investment to make.”

CS MEDICA is delightedly pleased with the DIAZ investment, which together with the approved 798,000 incentive/bonus warrants secure a very advantageous arrangement.  Initally DIAZ wanted to purchase a larger amount of shares in this Direct Issue, but we decided to limit the offer to the now issued 100,000 shares.  The funding, will be used to further accelerate the marketing of our newly introduced products, to reach as many of our potential customers as possible, says Lone Henriksen, CEO at CS MEDICA, and continues;

Although we are not in need of the funding coming from the DIAZ Direct issue, we saw an opportunity that we could not overpass.  With the agreements, with and cooperation network of DIAZ altogether focusing on future growth, and the kick start of our Investor Relation area, we secure a more thorough understanding of the company and the possibilities within the business area of CS MEDICA.”

Through the resolutions, the number of outstanding shares and votes increases by 100.000 shares, from 10.902.000 shares to 11.002.000 shares. The share capital increases by DKK 6.500 from DKK 708.630 to DKK 715.130, corresponding to a dilution of approximately 0,9 percent of the number of shares and votes in the Company.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.